Intestinal region-specific Wnt signalling profiles reveal interrelation between cell identity and oncogenic pathway activity in cancer development.

Cell of origin Intestinal cancer Wnt signalling

Journal

Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795

Informations de publication

Date de publication:
03 Dec 2020
Historique:
received: 08 03 2020
accepted: 16 11 2020
entrez: 9 12 2020
pubmed: 10 12 2020
medline: 10 12 2020
Statut: epublish

Résumé

Cancer results from the accumulation of mutations leading to the acquisition of cancer promoting characteristics such as increased proliferation and resistance to cell death. In colorectal cancer, an early mutation leading to such features usually occurs in the APC or CTNNB1 genes, thereby activating Wnt signalling. However, substantial phenotypic differences between cancers originating within the same organ, such as molecular subtypes, are not fully reflected by differences in mutations. Indeed, the phenotype seems to result from a complex interplay between the cell-intrinsic features and the acquired mutations, which is difficult to disentangle when established tumours are studied. We use a 3D in vitro organoid model to study the early phase of colorectal cancer development. From three different murine intestinal locations we grow organoids. These are transformed to resemble adenomas after Wnt activation through lentiviral transduction with a stable form of β-Catenin. The gene expression before and after Wnt activation is compared within each intestinal origin and across the three locations using RNA sequencing. To validate and generalize our findings, we use gene expression data from patients. In reaction to Wnt activation we observe downregulation of location specific genes and differentiation markers. A similar effect is seen in patient data, where genes with significant differential expression between the normal left and right colon are downregulated in the cancer samples. Furthermore, the signature of Wnt target genes differs between the three intestinal locations in the organoids. The location specific Wnt signatures are dominated by genes which have been lowly expressed in the tissue of origin, and are the targets of transcription factors that are activated following enhanced Wnt signalling. We observed that the region-specific cell identity has a substantial effect on the reaction to Wnt activation in a simple intestinal adenoma model. These findings provide a way forward in resolving the distinct biology between left- and right-sided human colon cancers with potential clinical relevance.

Sections du résumé

BACKGROUND BACKGROUND
Cancer results from the accumulation of mutations leading to the acquisition of cancer promoting characteristics such as increased proliferation and resistance to cell death. In colorectal cancer, an early mutation leading to such features usually occurs in the APC or CTNNB1 genes, thereby activating Wnt signalling. However, substantial phenotypic differences between cancers originating within the same organ, such as molecular subtypes, are not fully reflected by differences in mutations. Indeed, the phenotype seems to result from a complex interplay between the cell-intrinsic features and the acquired mutations, which is difficult to disentangle when established tumours are studied.
METHODS METHODS
We use a 3D in vitro organoid model to study the early phase of colorectal cancer development. From three different murine intestinal locations we grow organoids. These are transformed to resemble adenomas after Wnt activation through lentiviral transduction with a stable form of β-Catenin. The gene expression before and after Wnt activation is compared within each intestinal origin and across the three locations using RNA sequencing. To validate and generalize our findings, we use gene expression data from patients.
RESULTS RESULTS
In reaction to Wnt activation we observe downregulation of location specific genes and differentiation markers. A similar effect is seen in patient data, where genes with significant differential expression between the normal left and right colon are downregulated in the cancer samples. Furthermore, the signature of Wnt target genes differs between the three intestinal locations in the organoids. The location specific Wnt signatures are dominated by genes which have been lowly expressed in the tissue of origin, and are the targets of transcription factors that are activated following enhanced Wnt signalling.
CONCLUSION CONCLUSIONS
We observed that the region-specific cell identity has a substantial effect on the reaction to Wnt activation in a simple intestinal adenoma model. These findings provide a way forward in resolving the distinct biology between left- and right-sided human colon cancers with potential clinical relevance.

Identifiants

pubmed: 33292279
doi: 10.1186/s12935-020-01661-6
pii: 10.1186/s12935-020-01661-6
pmc: PMC7713000
doi:

Types de publication

Journal Article

Langues

eng

Pagination

578

Subventions

Organisme : Cancer Research UK
ID : A19274
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C14303/A17197
Pays : United Kingdom
Organisme : ZonMw
ID : Vidi 016.156.308
Pays : Netherlands
Organisme : Worldwide Cancer Research
ID : 14-1164
Pays : United Kingdom

Références

Cell Stem Cell. 2017 Jul 6;21(1):65-77.e5
pubmed: 28648363
Ann Oncol. 2017 Aug 1;28(8):1713-1729
pubmed: 28407110
Eur J Cancer. 2017 Jan;70:87-98
pubmed: 27907852
Nucleic Acids Res. 2015 Aug 18;43(14):6787-98
pubmed: 26117540
Nat Protoc. 2016 Sep;11(9):1650-67
pubmed: 27560171
Gastroenterology. 2006 Oct;131(4):1096-109
pubmed: 17030180
Cancer Res. 2006 Sep 1;66(17):8430-8
pubmed: 16951153
Nat Commun. 2016 Mar 09;7:10916
pubmed: 26956214
Cell. 1996 Aug 9;86(3):391-9
pubmed: 8756721
PLoS One. 2013;8(1):e54757
pubmed: 23382958
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
Nature. 2011 Jan 20;469(7330):314-22
pubmed: 21248838
Nat Med. 2015 Nov;21(11):1350-6
pubmed: 26457759
Nature. 2009 May 14;459(7244):262-5
pubmed: 19329995
Curr Protoc Stem Cell Biol. 2013 Nov 13;27:Unit 5A.6.
pubmed: 24510288
Mol Cell Biol. 1998 May;18(5):2901-11
pubmed: 9566909
Science. 1993 May 7;260(5109):816-9
pubmed: 8484122
J Biol Chem. 2012 Mar 9;287(11):8144-53
pubmed: 22262831
Gastroenterology. 2011 Nov;141(5):1762-72
pubmed: 21889923
Genome Biol. 2014;15(12):550
pubmed: 25516281
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7
pubmed: 10318916
Cell. 2002 Oct 18;111(2):241-50
pubmed: 12408868
Genome Biol. 2013 May 28;14(5):R50
pubmed: 23714178
EMBO J. 1997 Jul 1;16(13):3797-804
pubmed: 9233789
Gut. 2005 Mar;54(3):374-84
pubmed: 15710986
Nat Genet. 2003 Dec;35(4):323-30
pubmed: 14625550
Nucleic Acids Res. 2019 Jul 2;47(W1):W212-W224
pubmed: 31114921
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nature. 2014 Feb 27;506(7489):511-5
pubmed: 24413398
Nat Commun. 2019 Aug 19;10(1):3722
pubmed: 31427573
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6273-8
pubmed: 10339577
Nat Genet. 2002 Dec;32(4):594-605
pubmed: 12426568
Nature. 2019 Mar;567(7746):49-55
pubmed: 30814735
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Mol Cell Biol. 1994 Nov;14(11):7340-51
pubmed: 7935448
Nat Genet. 1998 Aug;19(4):379-83
pubmed: 9697701
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Stem Cells. 2014 May;32(5):1083-91
pubmed: 24496776
Gut. 2013 Jan;62(1):83-93
pubmed: 22287596
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
J Vis Exp. 2014 Aug 11;(90):e51765
pubmed: 25146755
Cell. 2015 Jun 18;161(7):1539-1552
pubmed: 26091037
Oncogene. 2013 Sep 26;32(39):4675-82
pubmed: 23085758
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Genes Dev. 2003 Jul 15;17(14):1709-13
pubmed: 12865297
EMBO J. 1998 Mar 2;17(5):1371-84
pubmed: 9482734
Genes Chromosomes Cancer. 2010 Aug;49(8):746-59
pubmed: 20544848
Ann Surg Oncol. 2008 Sep;15(9):2388-94
pubmed: 18622647
Bioinformatics. 2017 Feb 1;33(3):414-424
pubmed: 27694195
JCI Insight. 2016 Aug 18;1(13):e87899
pubmed: 27668286
Mod Pathol. 2013 Jun;26(6):825-34
pubmed: 23348904
Nucleic Acids Res. 2016 May 5;44(8):e71
pubmed: 26704973
Cell. 2019 Feb 21;176(5):1158-1173.e16
pubmed: 30712869
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Nature. 1992 Sep 17;359(6392):235-7
pubmed: 1528264
J Gastroenterol. 2015 Jan;50(1):46-57
pubmed: 24789573
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Cancer Res. 2018 Mar;16(3):476-485
pubmed: 29187560
Eur J Cancer. 2017 Oct;84:69-80
pubmed: 28787661
Gastroenterology. 2005 Aug;129(2):626-38
pubmed: 16083717
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Nature. 2017 Nov 16;551(7680):333-339
pubmed: 29144463
Cell. 2013 Jan 17;152(1-2):25-38
pubmed: 23273993
Nature. 2013 Dec 5;504(7478):143-147
pubmed: 24284627
Biochim Biophys Acta. 2011 Dec;1816(2):219-31
pubmed: 21855610
Gastroenterology. 2007 Feb;132(2):628-32
pubmed: 17320548
Nature. 1993 Jun 10;363(6429):558-61
pubmed: 8505985
Nature. 2010 Dec 23;468(7327):1095-9
pubmed: 21150899
BMC Cancer. 2010 Dec 21;10:688
pubmed: 21176147
Science. 1998 Sep 4;281(5382):1509-12
pubmed: 9727977
Cancer Res. 2005 Jan 1;65(1):166-76
pubmed: 15665292
Science. 1997 Mar 21;275(5307):1784-7
pubmed: 9065401
Cancer Res. 1993 Dec 15;53(24):5849-52
pubmed: 8261392
Cell. 2017 Jun 1;169(6):985-999
pubmed: 28575679
Development. 2006 Oct;133(20):4119-29
pubmed: 16971476

Auteurs

Ronja S Adam (RS)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Oncode Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Sanne M van Neerven (SM)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Oncode Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Cayetano Pleguezuelos-Manzano (C)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Oncode Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, Uppsalalaan 8, Utrecht, 3584 CT, The Netherlands.

Salvatore Simmini (S)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Oncode Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Research & Development Department at STEMCELL Technologies UK, 7100 Cambridge Research Park, Beach Drive Waterbeach, Cambridge, CB25 9TL, UK.

Nicolas Léveillé (N)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Oncode Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Nina E de Groot (NE)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.
Oncode Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands.

Andrew N Holding (AN)

Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.
The Alan Turing Institute, 96 Euston Road, Kings Cross, London, NW1 2DB, UK.
University of York, Wentworth Way, York, YO10 5DD, UK.

Florian Markowetz (F)

Cancer Research UK Cambridge Institute, University of Cambridge, Robinson Way, Cambridge, CB2 0RE, UK.

Louis Vermeulen (L)

Laboratory for Experimental Oncology and Radiobiology (LEXOR), Center for Experimental and Molecular Medicine (CEMM), Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. l.vermeulen@amsterdamumc.nl.
Oncode Institute, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands. l.vermeulen@amsterdamumc.nl.

Classifications MeSH